The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics

Current Drug Metabolism

Volumn 13, Issue 5, 2012, Pages 624-639

  Li, Yan ^a,b   Lu, Jun ^b   Paxton, James W ^a  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

ABC transporter; Pharmacokinetics; Phytochemicals; SLC transporter

Indexed keywords

6',7' DIHYDROXYBERGAMOTTIN; 6',7' EPOXYBERGAMOTTIN; ABC TRANSPORTER; ACACETIN; APIGENIN; AURANTIIN; BIOCHANIN A; CHRYSIN; CURCUMIN; DISULFIRAM; FANGQUINOLINE; GENISTEIN; GINSENOSIDE; GOMISIN A; HERBACEOUS AGENT; HESPERETIN; KAEMPFEROL; MEMBRANE PROTEIN; MYRICETIN; NARINGENIN; PLANT MEDICINAL PRODUCT; QUERCETIN; QUININE; ROBINETIN; SCHISANDRIN A; SCHISANDROL A; SCHIZANDRIN B; SOLUTE CARRIER TRANSPORTER; UNCLASSIFIED DRUG; UNINDEXED DRUG; XENOBIOTIC AGENT;

AQUEOUS SOLUTION; ARTICLE; BLOOD BRAIN BARRIER; CAPILLARY; CAPILLARY ENDOTHELIUM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; ENZYME DEGRADATION; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; HUMAN; LIVER EXCRETION; NONHUMAN; PHYTOCHEMISTRY; PLACENTA; SYSTEMIC CIRCULATION; URINARY EXCRETION;

EID: 84861916495     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211209050624     Document Type: Article

References (223)

1. Balunas, M. J.; Kinghorn, A. D. Drug discovery from medicinal plants. Life Sci., 2005, 78 (5), 431-441.
2. Espin, J. C.; Garcia-Conesa, M. T.; Tomas-Barberan, F. A. Nutraceuticals: facts and fiction. Phytochemistry, 2007, 68 (22-24), 2986-3008.
3. Duthie, S. J. Berry phytochemicals, genomic stability and cancer: evidence for chemoprotection at several stages in the carcinogenic process. Mol. Nutr. Food Res., 2007, 51 (6), 665-674.
4. Hooper, L.; Kroon, P. A.; Rimm, E. B.; Cohn, J. S.; Harvey, I.; Le Cornu, K. A.; Ryder, J. J.; Hall, W. L.; Cassidy, A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr., 2008, 88 (1), 38-50.
5. Kris-Etherton, P. M.; Hecker, K. D.; Bonanome, A.; Coval, S. M.; Binkoski, A. E.; Hilpert, K. F.; Griel, A. E.; Etherton, T. D. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med., 2002, 113 (9, Supplement 2), 71-88.
6. Dembinska-Kiec, A.; Mykkanen, O.; Kiec-Wilk, B.; Mykkanen, H. Antioxidant phytochemicals against type 2 diabetes. Br. J. Nutr., 2008, 99 E Suppl 1 ES109-117.
7. Russo, G. L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem. Pharmacol., 2007, 74 (4), 533-544.
8. Surh, Y. J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer, 2003, 3 (10), 768-780.
9. Aruoma, O. I.; Bahorun, T.; Jen, L.-S. Neuroprotection by bioactive components in medicinal and food plant extracts. Mutation Research/Reviews in Mutation Research, 2003, 544 (2-3), 203-215.
10. Khan, N.; Adhami, V. M.; Mukhtar, H. Apoptosis by dietary agents for prevention and treatment of cancer. Biochem. Pharmacol., 2008, 76 (11), 1333-1339.
11. Zhang, L.; Brett, C. M.; Giacomini, K. M. Role of organic cation transporters in drug absorption and elimination. Annu. Rev. Pharmacol. Toxicol., 1998, 38 431-460.
12. Borst, P.; Elferink, R. O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem., 2002, 71 537-592.
13. Faber, K. N.; Muller, M.; Jansen, P. L. Drug transport proteins in the liver. Adv Drug Deliv Rev, 2003, 55 (1), 107-124.
14. Shitara, Y.; Horie, T.; Sugiyama, Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci., 2006, 27 (5), 425-446.
15. Sarkadi, B.; Homolya, L.; Szakacs, G.; Varadi, A. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. Physiol. Rev., 2006, 86 (4), 1179-1236.
16. Zhang, Y.; Benet, L. Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet., 2001, 40 (3), 159-168.
17. Zhang, L.; Zuo, Z.; Lin, G. Intestinal and hepatic glucuronidation of flavonoids. Mol. Pharm., 2007, 4 (6), 833-845.
18. Zhou, S.; Lim, L. Y.; Chowbay, B. Herbal modulation of Pglycoprotein. Drug Metab. Rev., 2004, 36 (1), 57-104.
19. Morris, M. E.; Zhang, S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci., 2006, 78 (18), 2116-2130.
20. Zhang, W.; Han, Y.; Lim, S. L.; Lim, L. Y. Dietary regulation of Pgp function and expression. Expert Opin. Drug Metab. Toxicol., 2009, 5 (7), 789-801.
21. Shukla, S.; Wu, C. P.; Ambudkar, S. V. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin. Drug Metab. Toxicol., 2008, 4 (2), 205-223.
22. Hu, M.; Chen, J.; Lin, H. Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J. Pharmacol. Exp. Ther., 2003, 307 (1), 314-321.
23. Lancon, A.; Hanet, N.; Jannin, B.; Delmas, D.; Heydel, J. M.; Lizard, G.; Chagnon, M. C.; Artur, Y.; Latruffe, N. Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab. Dispos., 2007, 35 (5), 699-703.
24. Petri, N.; Tannergren, C.; Holst, B.; Mellon, F. A.; Bao, Y.; Plumb, G. W.; Bacon, J.; O'Leary, K. A.; Kroon, P. A.; Knutson, L.; Forsell, P.; Eriksson, T.; Lennernas, H.; Williamson, G. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab. Dispos., 2003, 31 (6), 805-813.
25. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek- Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development. Nat. Rev. Drug Discov., 2010, 9 (3), 215-236.
26. Shukla, S.; Zaher, H.; Hartz, A.; Bauer, B.; Ware, J. A.; Ambudkar, S. V. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm. Res., 2009, 26 (2), 480-487.
27. Wang, X.; Morris, M. E. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab. Dispos., 2007, 35 (2), 268-274.
28. Kim, K. A.; Park, P. W.; Park, J. Y. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of Pglycoprotein, in healthy volunteers. Eur. J. Clin. Pharmacol., 2009, 65 (6), 609-614.
29. Anand, P.; Kunnumakkara, A. B.; Newman, R. A.; Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol. Pharm., 2007, 4 (6), 807-818.
30. Sousa, T.; Paterson, R.; Moore, V.; Carlsson, A.; Abrahamsson, B.; Basit, A. W. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm., 2008, 363 (1-2), 1-25.
31. Walle, T.; Browning, A. M.; Steed, L. L.; Reed, S. G.; Walle, U. K. Flavonoid glucosides are hydrolyzed and thus activated in the oral cavity in humans. J. Nutr., 2005, 135 (1), 48-52.
32. Crespy, V.; Morand, C.; Besson, C.; Manach, C.; Demigne, C.; Remesy, C. Quercetin, but not its glycosides, is absorbed from the rat stomach. J. Agric. Food Chem., 2002, 50 (3), 618-621.
33. Litman, T.; Druley, T. E.; Stein, W. D.; Bates, S. E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci., 2001, 58 (7), 931-959.
34. Taipalensuu, J.; Tornblom, H.; Lindberg, G.; Einarsson, C.; Sjoqvist, F.; Melhus, H.; Garberg, P.; Sjostrom, B.; Lundgren, B.; Artursson, P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther., 2001, 299 (1), 164-170.
35. Takano, M.; Yumoto, R.; Murakami, T. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther., 2006, 109 (1-2), 137-161.
36. Kullak-Ublick, G. A.; Ismair, M. G.; Stieger, B.; Landmann, L.; Huber, R.; Pizzagalli, F.; Fattinger, K.; Meier, P. J.; Hagenbuch, B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 2001, 120 (2), 525-533.
37. Tamai, I. Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev, 2011.
38. Jonker, J. W.; Wagenaar, E.; Mol, C. A.; Buitelaar, M.; Koepsell, H.; Smit, J. W.; Schinkel, A. H. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Bio, 2001, 21 (16), 5471-5477.
39. Jonker, J. W.; Schinkel, A. H. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther., 2004, 308 (1), 2-9.
40. Ming, X.; Thakker, D. R. Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil. Biochem. Pharmacol., 2009.
41. Prime-Chapman, H. M.; Fearn, R. A.; Cooper, A. E.; Moore, V.; Hirst, B. H. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J. Pharmacol. Exp. Ther., 2004, 311 (2), 476-484.
42. Kellett, G. L. The facilitated component of intestinal glucose absorption. J. Physiol., 2001, 531 (Pt 3), 585-595.
43. Higgins, C. F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol., 1992, 8 67-113.
44. Drach, J.; Gsur, A.; Hamilton, G.; Zhao, S.; Angerler, J.; Fiegl, M.; Zojer, N.; Raderer, M.; Haberl, I.; Andreeff, M.; Huber, H. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood, 1996, 88 (5), 1747-1754.
45. de Castro, W. V.; Mertens-Talcott, S.; Derendorf, H.; Butterweck, V. Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J. Pharm. Sci., 2007, 96 (10), 2808-2817.
46. Choi, S. U.; Park, S. H.; Kim, K. H.; Choi, E. J.; Kim, S.; Park, W. K.; Zhang, Y. H.; Kim, H. S.; Jung, N. P.; Lee, C. O. The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer. Drugs, 1998, 9 (3), 255-261.
47. Orlowski, S.; Valente, D.; Garrigos, M.; Ezan, E. Bromocriptine modulates P-glycoprotein function. Biochem. Biophys. Res. Commun., 1998, 244 (2), 481-488.
48. Robey, R. W.; Shukla, S.; Finley, E. M.; Oldham, R. K.; Barnett, D.; Ambudkar, S. V.; Fojo, T.; Bates, S. E. Inhibition of Pglycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem. Pharmacol., 2008, 75 (6), 1302-1312.
49. Hsiao, P.; Bui, T.; Ho, R. J.; Unadkat, J. D. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab. Dispos., 2008, 36 (3), 481-484.
50. Dresser, G. K.; Bailey, D. G. The effects of fruit juices on drug disposition: a new model for drug interactions. European J Clin Inves, 2003, 33 10-16.
51. Perloff, M. D.; von Moltke, L. L.; Stormer, E.; Shader, R. I.; Greenblatt, D. J. Saint John's wort: an in vitro analysis of Pglycoprotein induction due to extended exposure. Br. J. Pharmacol., 2001, 134 (8), 1601-1608.
52. Zimmermann, C.; Gutmann, H.; Hruz, P.; Gutzwiller, J.-P.; Beglinger, C.; Drewe, J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab. Dispos., 2005, 33 (2), 219-224.
53. Englund, G.; Rorsman, F.; Ronnblom, A.; Karlbom, U.; Lazorova, L.; Grasjo, J.; Kindmark, A.; Artursson, P. Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci., 2006, 29 (3-4), 269-277.
54. Gutmann, H.; Hruz, P.; Zimmermann, C.; Beglinger, C.; Drewe, J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem. Pharmacol., 2005, 70 (5), 695-699.
55. Maliepaard, M.; Scheffer, G. L.; Faneyte, I. F.; van Gastelen, M. A.; Pijnenborg, A. C.; Schinkel, A. H.; van De Vijver, M. J.; Scheper, R. J.; Schellens, J. H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 2001, 61 (8), 3458-3464.
56. Enokizono, J.; Kusuhara, H.; Sugiyama, Y. Effect of breast cancer resistance protein (bcrp/abcg2) on the disposition of phytoestrogens. Mol. Pharmacol., 2007, 72 (4), 967-975.
57. Dreiseitel, A.; Oosterhuis, B.; Vukman, K. V.; Schreier, P.; Oehme, A.; Locher, S.; Hajak, G.; Sand, P. G. Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br. J. Pharmacol., 2009, 158 (8), 1942-1950.
58. An, G.; Gallegos, J.; Morris, M. E. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab. Dispos., 2011, 39 (3), 426-432.
59. Breedveld, P.; Pluim, D.; Cipriani, G.; Dahlhaus, F.; van Eijndhoven, M. A.; de Wolf, C. J.; Kuil, A.; Beijnen, J. H.; Scheffer, G. L.; Jansen, G.; Borst, P.; Schellens, J. H. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol. Pharmacol., 2007, 71 (1), 240-249.
60. Jodoin, J.; Demeule, M.; Beliveau, R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta, 2002, 1542 (1-3), 149-159.
61. Zhang, S.; Morris, M. E. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm. Res., 2003, 20 (8), 1184-1191.
62. Taur, J. S.; Rodriguez-Proteau, R. Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica, 2008, 38 (12), 1536-1550.
63. Wang, E. J.; Barecki-Roach, M.; Johnson, W. W. Elevation of Pglycoprotein function by a catechin in green tea. Biochem. Biophys. Res. Commun., 2002, 297 (2), 412-418.
64. Castro, A. F.; Altenberg, G. A. Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem. Pharmacol., 1997, 53 (1), 89-93.
65. Pick, A.; Muller, H.; Mayer, R.; Haenisch, B.; Pajeva, I. K.; Weigt, M.; Bonisch, H.; Muller, C. E.; Wiese, M. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg. Med. Chem., 2011, 19 (6), 2090-2102.
66. Moon, Y. J.; Morris, M. E. Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in rats. Mol. Pharm., 2007, 4 (6), 865-872.
67. Cermak, R.; Wolffram, S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr. Drug Metab., 2006, 7 (7), 729-744.
68. Hagenbuch, B.; Meier, P. J. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta - Biomembranes, 2003, 1609 (1), 1-18.
69. Roth, M.; Timmermann, B. N.; Hagenbuch, B. Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab. Dispos., 2011, 39 (5), 920-926.
70. Mandery, K.; Bujok, K.; Schmidt, I.; Keiser, M.; Siegmund, W.; Balk, B.; Konig, J.; Fromm, M. F.; Glaeser, H. Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem. Pharmacol., 2010, 80 (11), 1746-1753.
71. Yamakawa, Y.; Hamada, A.; Shuto, T.; Yuki, M.; Uchida, T.; Kai, H.; Kawaguchi, T.; Saito, H. Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. Clin. Pharmacol. Ther., 2011, 90 (1), 157-163.
72. Shirasaka, Y.; Li, Y.; Shibue, Y.; Kuraoka, E.; Spahn-Langguth, H.; Kato, Y.; Langguth, P.; Tamai, I. Concentration-dependent effect of naringin on intestinal absorption of 1-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm. Res., 2009, 26 (3), 560-567.
73. Fuchikami, H.; Satoh, H.; Tsujimoto, M.; Ohdo, S.; Ohtani, H.; Sawada, Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos., 2006, 34 (4), 577-582.
74. Nait Chabane, M.; Al Ahmad, A.; Peluso, J.; Muller, C. D.; Ubeaud, G. Quercetin and naringenin transport across human intestinal Caco-2 cells. J. Pharm. Pharmacol., 2009, 61 (11), 1473-1483.
75. Sparreboom, A.; Van Asperen, J.; Mayer, U. limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U. S. A., 1997, 94 2031-2035.
76. van de Steeg, E.; van Esch, A.; Wagenaar, E.; van der Kruijssen, C. M.; van Tellingen, O.; Kenworthy, K. E.; Schinkel, A. H. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin. Cancer Res., 2011, 17 (2), 294-301.
77. Banfield, C.; Gupta, S.; Marino, M.; Lim, J.; Affrime, M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin. Pharmacokinet., 2002, 41 (4), 311-318.
78. Dresser, G. K.; Bailey, D. G.; Leake, B. F.; Schwarz, U. I.; Dawson, P. A.; Freeman, D. J.; Kim, R. B. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther., 2002, 71 (1), 11-20.
79. Schwarz, U. I.; Seemann, D.; Oertel, R.; Miehlke, S.; Kuhlisch, E.; Fromm, M. F.; Kim, R. B.; Bailey, D. G.; Kirch, W. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther., 2005, 77 (4), 291-301.
80. Muller, J.; Lips, K. S.; Metzner, L.; Neubert, R. H.; Koepsell, H.; Brandsch, M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem. Pharmacol., 2005, 70 (12), 1851-1860.
81. Gorboulev, V.; Ulzheimer, J. C.; Akhoundova, A.; Ulzheimer- Teuber, I.; Karbach, U.; Quester, S.; Baumann, C.; Lang, F.; Busch, A. E.; Koepsell, H. Cloning and characterization of two human polyspecific organic cation transporters. DNA & Cell Biology., 1997, 16 (7), 871-881.
82. Zhang, L.; Dresser, M.; Gray, A.; Yost, S.; Terashita, S.; Giacomini, K. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol., 1997, 51 (6), 913-921.
83. Hayer-Zillgen, M.; Bruss, M.; Bonisch, H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol., 2002, 136 (6), 829-836.
84. Zhang, L.; Schaner, M. E.; Giacomini, K. M. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J. Pharmacol. Exp. Ther., 1998, 286 (1), 354-361.
85. van Montfoort, J. E.; Muller, M.; Groothuis, G. M.; Meijer, D. K.; Koepsell, H.; Meier, P. J. Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J. Pharmacol. Exp. Ther., 2001, 298 (1), 110-115.
86. Sweet, D. H.; Miller, D. S.; Pritchard, J. B. Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J. Biol. Chem., 2001, 276 (45), 41611-41619.
87. Cermak, R.; Landgraf, S.; Wolffram, S. Quercetin glucosides inhibit glucose uptake into brush-border-membrane vesicles of porcine jejunum. Br. J. Nutr., 2004, 91 (6), 849-855.
88. Walgren, R. A.; Lin, J. T.; Kinne, R. K.; Walle, T. Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodiumdependent glucose transporter SGLT1. J. Pharmacol. Exp. Ther., 2000, 294 (3), 837-843.
89. Kottra, G.; Daniel, H. Flavonoid glycosides are not transported by the human Na+/glucose transporter when expressed in Xenopus laevis oocytes, but effectively inhibit electrogenic glucose uptake. J. Pharmacol. Exp. Ther., 2007, 322 (2), 829-835.
90. Cunningham, P.; Afzal-Ahmed, I.; Naftalin, R. J. Docking studies show that D-glucose and quercetin slide through the transporter GLUT1. J. Biol. Chem., 2006, 281 (9), 5797-5803.
91. Strobel, P.; Allard, C.; Perez-Acle, T.; Calderon, R.; Aldunate, R.; Leighton, F. Myricetin, quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes. Biochem. J., 2005, 386 (Pt 3), 471-478.
92. Lewis, D. F.; Ito, Y. Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions. Expert Opin. Drug Metab. Toxicol., 2008, 4 (9), 1181-1186.
93. Gan, L. S.; Moseley, M. A.; Khosla, B.; Augustijns, P. F.; Bradshaw, T. P.; Hendren, R. W.; Thakker, D. R. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab. Dispos., 1996, 24 (3), 344-349.
94. Watkins, P. B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev, 1997, 27 (2-3), 161-170.
95. Wacher, V. J.; Salphati, L.; Benet, L. Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev, 2001, 46 89-102.
96. Benet, L. Z. The drug transporter-metabolism alliance: Uncovering and defining the interplay. Mol. Pharm., 2009, 6 (6), 1631-1643.
97. Choi, J. S.; Choi, H. K.; Shin, S. C. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int. J. Pharm., 2004, 275 (1-2), 165-170.
98. Choi, J. S.; Jo, B. W.; Kim, Y. C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm. Biopharm., 2004, 57 (2), 313-318.
99. Lambert, J. D.; Sang, S.; Yang, C. S. Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol. Pharm., 2007, 4 (6), 819-825.
100. Yang, C. S.; Lambert, J. D.; Ju, J.; Lu, G.; Sang, S. Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol. Appl. Pharmacol., 2007, 224 (3), 265-273.
101. Janisch, K. M.; Williamson, G.; Needs, P.; Plumb, G. W. Properties of quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. Free Radic. Res., 2004, 38 (8), 877-884.
102. Lotsch, J.; Geisslinger, G. Morphine-6-glucuronide: an analgesic of the future? Clin. Pharmacokinet., 2001, 40 (7), 485-499.
103. Kosoglou, T.; Statkevich, P.; Johnson-Levonas, A. O.; Paolini, J. F.; Bergman, A. J.; Alton, K. B. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet., 2005, 44 (5), 467-494.
104. Stevenson, D. E.; Cooney, J. M.; Jensen, D. J.; Wibisono, R.; Adaim, A.; Skinner, M. A.; Zhang, J. Comparison of enzymically glucuronidated flavonoids with flavonoid aglycones in an in vitro cellular model of oxidative stress protection. In vitro Cell. Dev. Biol. Anim., 2008, 44 (3-4), 73-80.
105. Suri, S.; Taylor, M. A.; Verity, A.; Tribolo, S.; Needs, P. W.; Kroon, P. A.; Hughes, D. A.; Wilson, V. G. A comparative study of the effects of quercetin and its glucuronide and sulfate metabolites on human neutrophil function in vitro. Biochem. Pharmacol., 2008, 76 (5), 645-653.
106. Day, A. J.; Bao, Y.; Morgan, M. R.; Williamson, G. Conjugation position of quercetin glucuronides and effect on biological activity. Free Radic. Biol. Med., 2000, 29 (12), 1234-1243.
107. O'Leary, K. A.; Day, A. J.; Needs, P. W.; Mellon, F. A.; O'Brien, N. M.; Williamson, G. Metabolism of quercetin-7- and quercetin-3- glucuronides by an in vitro hepatic model: the role of human betaglucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem. Pharmacol., 2003, 65 (3), 479-491.
108. Bartholome, R.; Haenen, G.; Hollman, C. H.; Bast, A.; Dagnelie, P. C.; Roos, D.; Keijer, J.; Kroon, P. A.; Needs, P. W.; Arts, C. W. Deconjugation kinetics of glucuronidated phase II flavonoid metabolites by beta-glucuronidase from neutrophils. Drug Metab. Pharmacokinet., 2010, 25 (4), 379-387.
109. Xing, J.; Chen, X.; Zhong, D. Absorption and enterohepatic circulation of baicalin in rats. Life Sci., 2005, 78 (2), 140-146.
110. Li, Y.; Fawcett, J. P.; Zhang, H.; Tucker, I. G. Transport and metabolism of MitoQ10, a mitochondria-targeted antioxidant, in Caco-2 cell monolayers. J. Pharm. Pharmacol., 2007, 59 (4), 503-511.
111. Ebert, B.; Seidel, A.; Lampen, A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis, 2005, 26 (10), 1754-1763.
112. Zhang, L.; Zheng, Y.; Chow, M. S. S.; Zuo, Z. Investigation of intestinal absorption and disposition of green tea catechins by Caco-2 monolayer model. Int. J. Pharm., 2004, 287 1-12.
113. Juan, M. E.; Gonzalez-Pons, E.; Planas, J. M. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J. Nutr., 2010, 140 (3), 489-495.
114. Sesink, A. L.; Arts, I. C.; de Boer, V. C.; Breedveld, P.; Schellens, J. H.; Hollman, P. C.; Russel, F. G. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol. Pharmacol., 2005, 67 (6), 1999-2006.
115. Walle, U. K.; Galijatovic, A.; Walle, T. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharm, 1999, 58 (3), 431-438.
116. Walle, T.; Otake, Y.; Brubaker, J. A.; Walle, U. K.; Halushka, P. V. Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br. J. Clin. Pharmacol., 2001, 51 (2), 143-146.
117. Huls, M.; Russel, F. G.; Masereeuw, R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J. Pharmacol. Exp. Ther., 2009, 328 (1), 3-9.
118. Mruk, D. D.; Su, L.; Cheng, C. Y. Emerging role for drug transporters at the blood-testis barrier. Trends Pharmacol. Sci., 2011, 32 (2), 99-106.
119. Pardridge, W.M. The Blood Brain Barrier. Culture and Molecular Biology: Review Press, NY 1993.
120. Terasaki, T.; Hosoya, K. The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev, 1999, 36 (2-3), 195-209.
121. Tamai, I.; Tsuji, A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci., 2000, 89 (11), 1371-1388.
122. Ohtsuki, S.; Terasaki, T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res., 2007, 24 (9), 1745-1758.
123. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C.; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem., 2011, 117 (2), 333-345.
124. Cornford, E. M.; Hyman, S. Blood-brain barrier permeability to small and large molecules. Adv Drug Deliv Rev, 1999, 36 (2-3), 145-163.
125. Gao, B.; Hagenbuch, B.; Kullak-Ublick, G. A.; Benke, D.; Aguzzi, A.; Meier, P. J. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Ther., 2000, 294 (1), 73-79.
126. Lee, W.; Glaeser, H.; Smith, L. H.; Roberts, R. L.; Moeckel, G. W.; Gervasini, G.; Leake, B. F.; Kim, R. B. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem., 2005, 280 (10), 9610-9617.
127. Bronger, H.; Konig, J.; Kopplow, K.; Steiner, H. H.; Ahmadi, R.; Herold-Mende, C.; Keppler, D.; Nies, A. T. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res., 2005, 65 (24), 11419-11428.
128. Dauchy, S.; Miller, F.; Couraud, P. O.; Weaver, R. J.; Weksler, B.; Romero, I. A.; Scherrmann, J. M.; De Waziers, I.; Decleves, X. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem. Pharmacol., 2009, 77 (5), 897-909.
129. Kubota, H.; Ishihara, H.; Langmann, T.; Schmitz, G.; Stieger, B.; Wieser, H. G.; Yonekawa, Y.; Frei, K. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res., 2006, 68 (3), 213-228.
130. Linnet, K.; Ejsing, T. B. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur. Neuropsychopharmacol., 2008, 18 (3), 157-169.
131. Eisenblatter, T.; Huwel, S.; Galla, H. J. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res., 2003, 971 (2), 221-231.
132. Cisternino, S.; Mercier, C.; Bourasset, F.; Roux, F.; Scherrmann, J. M. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res., 2004, 64 (9), 3296-3301.
133. Yu, X. Y.; Lin, S. G.; Chen, X.; Zhou, Z. W.; Liang, J.; Duan, W.; Chowbay, B.; Wen, J. Y.; Chan, E.; Cao, J.; Li, C. G.; Zhou, S. F. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. Curr. Drug Metab., 2007, 8 (4), 365-378.
134. Yu, X. Y.; Lin, S. G.; Zhou, Z. W.; Chen, X.; Liang, J.; Yu, X. Q.; Chowbay, B.; Wen, J. Y.; Duan, W.; Chan, E.; Li, X. T.; Cao, J.; Li, C. G.; Xue, C. C.; Zhou, S. F. Role of P-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of Glycyrrhiza glabra. Pharm. Res., 2007, 24 (9), 1668-1690.
135. Tsai, T. H.; Lee, C. H.; Yeh, P. H. Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis. Br. J. Pharmacol., 2001, 134 (6), 1245-1252.
136. Lee, Y. J.; Kusuhara, H.; Jonker, J. W.; Schinkel, A. H.; Sugiyama, Y. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J. Pharmacol. Exp. Ther., 2005, 312 (1), 44-52.
137. Youdim, K. A.; Qaiser, M. Z.; Begley, D. J.; Rice-Evans, C. A.; Abbott, N. J. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med., 2004, 36 (5), 592-604.
138. Dhillon, N.; Aggarwal, B. B.; Newman, R. A.; Wolff, R. A.; Kunnumakkara, A. B.; Abbruzzese, J. L.; Ng, C. S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res., 2008, 14 (14), 4491-4499.
139. Jonker, J. W.; Smit, J. W.; Brinkhuis, R. F.; Maliepaard, M.; Beijnen, J. H.; Schellens, J. H.; Schinkel, A. H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst., 2000, 92 (20), 1651-1656.
140. Evseenko, D. A.; Paxton, J. W.; Keelan, J. A. ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2006, 290 (5), R1357-1365.
141. Balakrishnan, B.; Thorstensen, E. B.; Ponnampalam, A. P.; Mitchell, M. D. Transplacental transfer and biotransformation of genistein in human placenta. Placenta, 2010, 31 (6), 506-511.
142. North, K.; Golding, J. A maternal vegetarian diet in pregnancy is associated with hypospadias. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. BJU Int., 2000, 85 (1), 107-113.
143. Meier, P. J.; Eckhardt, U.; Schroeder, A.; Hagenbuch, B.; Stieger, B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology, 1997, 26 1667-1677.
144. Ichikawa, M.; Yoshimura, A.; Sumizawa, T.; Shudo, N.; Kuwazuru, Y.; Furukawa, T.; Akiyama, S. Interaction of organic chemicals with P-glycoprotein in the adrenal gland, kidney, and a multidrug-resistant KB cell. J Bio Chem, 1991, 266 (2), 903-908.
145. Leslie, E. M.; Deeley, R. G.; Cole, S. P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol., 2005, 204 (3), 216-237.
146. Huls, M.; Brown, C. D.; Windass, A. S.; Sayer, R.; van den Heuvel, J. J.; Heemskerk, S.; Russel, F. G.; Masereeuw, R. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int., 2008, 73 (2), 220-225.
147. van Aubel, R. A.; Smeets, P. H.; Peters, J. G.; Bindels, R. J.; Russel, F. G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol., 2002, 13 (3), 595-603.
148. Hooiveld, G. J. E. J.; van Montfoort, J. E.; Meijer, D. K. F.; Muller, M. Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. Eur. J. Pharm. Sci., 2000, 12 (1), 13-30.
149. Wong, C. C.; Botting, N. P.; Orfila, C.; Al-Maharik, N.; Williamson, G. Flavonoid conjugates interact with organic anion transporters (OATs) and attenuate cytotoxicity of adefovir mediated by organic anion transporter 1 (OAT1/SLC22A6). Biochem. Pharmacol., 2011, 81 (7), 942-949.
150. Hsiang, B.; Zhu, Y.; Wang, Z.; Wu, Y.; Sasseville, V.; Yang, W.- P.; Kirchgessner, T. G. A novel human hepatic organic anion transporting polypeptide (oatp2). identification of a liver-specific human organic anion transporting
151. Ieiri, I.; Suwannakul, S.; Maeda, K.; Uchimaru, H.; Hashimoto, K.; Kimura, M.; Fujino, H.; Hirano, M.; Kusuhara, H.; Irie, S.; Higuchi, S.; Sugiyama, Y. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther., 2007, 82 (5), 541-547.
152. Ieiri, I.; Higuchi, S.; Sugiyama, Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol., 2009, 5 (7), 703-729.
153. Kalliokoski, A.; Niemi, M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol., 2009, 158 (3), 693-705.
154. Kopplow, K.; Letschert, K.; Konig, J.; Walter, B.; Keppler, D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol., 2005, 68 (4), 1031-1038.
155. Tirona, R. G.; Leake, B. F.; Wolkoff, A. W.; Kim, R. B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther., 2003, 304 (1), 223-228.
156. Cvetkovic, M.; Leake, B.; Fromm, M. F.; Wilkinson, G. R.; Kim, R. B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos., 1999, 27 (8), 866-871.
157. Wang, X.; Wolkoff, A. W.; Morris, M. E. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab. Dispos., 2005, 33 (11), 1666-1672.
158. Roth, M.; Araya, J. J.; Timmermann, B. N.; Hagenbuch, B. Isolation of modulators of the liver specific organic anion transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae). J. Pharmacol. Exp. Ther., 2011
159. Bachmakov, I.; Glaeser, H.; Fromm, M. F.; Konig, J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes, 2008, 57 (6), 1463-1469.
160. Miranda, S. R.; Lee, J. K.; Brouwer, K. L.; Wen, Z.; Smith, P. C.; Hawke, R. L. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2). Drug Metab. Dispos., 2008, 36 (11), 2219-2226.
161. Keitel, V.; Kartenbeck, J.; Nies, A. T.; Spring, H.; Brom, M.; Keppler, D. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology, 2000, 32 (6), 1317-1328.
162. Ros, J. E.; Roskams, T. A.; Geuken, M.; Havinga, R.; Splinter, P. L.; Petersen, B. E.; LaRusso, N. F.; van der Kolk, D. M.; Kuipers, F.; Faber, K. N.; Muller, M.; Jansen, P. L. ATP binding cassette transporter gene expression in rat liver progenitor cells. Gut, 2003, 52 (7), 1060-1067.
163. Zhang, W.; Tan, T. M.; Lim, L. Y. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab. Dispos., 2007, 35 (1), 110-115.
164. Lim, S. L.; Lim, L. Y. Effects of citrus fruit juices on cytotoxicity and drug transport pathways of Caco-2 cell monolayers. Int. J. Pharm., 2006, 307 (1), 42-50.
165. Lim, S. C.; Im, Y. B.; Bae, C. S.; Han, S. I.; Kim, S. E.; Han, H. K. Protective effect of morin on the imipenem-induced nephrotoxicity in rabbits. Arch. Pharm. Res., 2008, 31 1060-1065.
166. Williamson, G.; Aeberli, I.; Miguet, L.; Zhang, Z.; Sanchez, M. B.; Crespy, V.; Barron, D.; Needs, P.; Kroon, P. A.; Glavinas, H.; Krajcsi, P.; Grigorov, M. Interaction of positional isomers of quercetin glucuronides with the transporter ABCC2 (cMOAT, MRP2). Drug Metab. Dispos., 2007, 35 (8), 1262-1268.
167. Molnar, J.; Gyemant, N.; Tanaka, M.; Hohmann, J.; Bergmann- Leitner, E.; Molnar, P.; Deli, J.; Didiziapetris, R.; Ferreira, M. J. Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids. Curr. Pharm. Des., 2006, 12 (3), 287-311.
168. Patel, J.; Buddha, B.; Dey, S.; Pal, D.; Mitra, A. K. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am. J. Ther., 2004, 11 (4), 262-277.
169. Durr, D.; Stieger, B.; Kullak-Ublick, G. A.; Rentsch, K. M.; Steinert, H. C.; Meier, P. J.; Fattinger, K. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther., 2000, 68 (6), 598-604.
170. Hennessy, M.; Kelleher, D.; Spiers, J. P.; Barry, M.; Kavanagh, P.; Back, D.; Mulcahy, F.; Feely, J. St John's wort increases expression of P-glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol., 2002, 53 (1), 75-82.
171. Perloff, M. D.; Von Moltke, L. L.; Marchand, J. E.; Greenblatt, D. J. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J. Pharm. Sci., 2001, 90 (11), 1829-1837.
172. Piscitelli, S. C.; Burstein, A. H.; Chaitt, D.; Alfaro, R. M.; Falloon, J. Indinavir concentrations and St John's wort. Lancet, 2000, 355 (9203), 547-548.
173. Moore, L. B.; Goodwin, B.; Jones, S. A.; Wisely, G. B.; Serabjit- Singh, C. J.; Willson, T. M.; Collins, J. L.; Kliewer, S. A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U. S. A., 2000, 97 (13), 7500-7502.
174. Bailey, D. G.; Dresser, G. K.; Leake, B. F.; Kim, R. B. Naringin is a major and selective clinical inhibitor of organic aniontransporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther., 2007, 81 (4), 495-502.
175. Bailey, D. G.; Spence, J. D.; Munoz, C.; Arnold, J. M. Interaction of citrus juices with felodipine and nifedipine. Lancet, 1991, 337 (8736), 268-269.
176. Dahan, A.; Altman, H. Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur. J. Clin. Nutr., 2004, 58 (1), 1-9.
177. Zhou, S.; Gao, Y.; Jiang, W.; Huang, M.; Xu, A.; Paxton, J. W. Interactions of herbs with cytochrome P450. Drug Metab. Rev., 2003, 35 (1), 35-98.
178. Rodeiro, I.; Donato, M. T.; Lahoz, A.; Garrido, G.; Delgado, R.; Gomez-Lechon, M. J. Interactions of polyphenols with the P450 system: possible implications on human therapeutics. Mini Rev. Med. Chem., 2008, 8 (2), 97-106.
179. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5 (6), 493-506.
180. Murakami, T.; Takano, M. Intestinal efflux transporters and drug absorption. Expert Opin. Drug Metab. Toxicol., 2008, 4 (7), 923-939.
181. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F. M.; Torti, S. V. Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci., 2008, 65 (11), 1631-1652.
182. Bisht, S.; Feldmann, G.; Soni, S.; Ravi, R.; Karikar, C.; Maitra, A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology, 2007, 5 3.
183. Chen, C.; Johnston, T. D.; Jeon, H.; Gedaly, R.; McHugh, P. P.; Burke, T. G.; Ranjan, D. An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int. J. Pharm., 2009, 366 (1-2), 133-139.
184. Cui, J.; Yu, B.; Zhao, Y.; Zhu, W.; Li, H.; Lou, H.; Zhai, G. Enhancement of oral absorption of curcumin by selfmicroemulsifying drug delivery systems. Int. J. Pharm., 2009, 371 (1-2), 148-155.
185. Santos, A. C.; Veiga, F.; Ribeiro, A. J. New delivery systems to improve the bioavailability of resveratrol. Expert Opin. Drug Deliv., 2011
186. Chavanpatil, M. D.; Patil, Y.; Panyam, J. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int. J. Pharm., 2006, 320 (1-2), 150-156.
187. Zhang, Y.; Hu, Z.; Ye, M.; Pan, Y.; Chen, J.; Luo, Y.; He, L.; Wang, J. Effect of poly(ethylene glycol)-block-polylactide nanoparticles on hepatic cells of mouse: low cytotoxicity, but efflux of the nanoparticles by ATP-binding cassette transporters. Eur. J. Pharm. Biopharm., 2007, 66 (2), 268-280.
188. Holpuch, A. S.; Hummel, G. J.; Tong, M.; Seghi, G. A.; Pei, P.; Ma, P.; Mumper, R. J.; Mallery, S. R. Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharm. Res., 2011, 27 (7), 1224-1236.
189. Yamagata, T.; Kusuhara, H.; Morishita, M.; Takayama, K.; Benameur, H.; Sugiyama, Y. Effect of excipients on breast cancer resistance protein substrate uptake activity. J. Control. Release, 2007, 124 (1-2), 1-5.
190. Hiasa, M.; Matsumoto, T.; Komatsu, T.; Moriyama, Y. Wide variety of locations for rodent MATE1, a transporter protein that mediates the final excretion step for toxic organic cations. Am. J. Physiol. Cell Physiol., 2006, 291 (4), C678-686.
191. Wenzel, U.; Kuntz, S.; Daniel, H. Flavonoids with epidermal growth factor-receptor tyrosine kinase inhibitory activity stimulate PEPT1-mediated cefixime uptake into human intestinal epithelial cells. J. Pharmacol. Exp. Ther., 2001, 299 (1), 351-357.
192. Anuchapreeda, S.; Leechanachai, P.; Smith, M. M.; Ambudkar, S. V.; Limtrakul, P. N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol., 2002, 64 (4), 573-582.
193. Versantvoort, C. H.; Schuurhuis, G. J.; Pinedo, H. M.; Eekman, C. A.; Kuiper, C. M.; Lankelma, J.; Broxterman, H. J. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br. J. Cancer, 1993, 68 (5), 939-946.
194. Versantvoort, C. H.; Broxterman, H. J.; Lankelma, J.; Feller, N.; Pinedo, H. M. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol., 1994, 48 (6), 1129-1136.
195. Versantvoort, C. H.; Rhodes, T.; Twentyman, P. R. Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br. J. Cancer, 1996, 74 (12), 1949-1954.
196. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. The multidrug resistance protein family. Biochim. Biophys. Acta, 1999, 1461 347-357.
197. Zhou, S. F.; Wang, L. L.; Di, Y. M.; Xue, C. C.; Duan, W.; Li, C. G.; Li, Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem., 2008, 15 (20), 1981-2039.
198. Wu, C. P.; Calcagno, A. M.; Hladky, S. B.; Ambudkar, S. V.; Barrand, M. A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J., 2005, 272 (18), 4725-4740.
199. Li, Y.; Revalde, J. L.; Reid, G.; Paxton, J. W. Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemother. Pharmacol., 2011, 68 (3), 603-610.
200. de Wolf, C.; Jansen, R.; Yamaguchi, H.; de Haas, M.; van de Wetering, K.; Wijnholds, J.; Beijnen, J.; Borst, P. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol. Cancer Ther., 2008, 7 (9), 3092-3102.
201. Holland, M. L.; Lau, D. T.; Allen, J. D.; Arnold, J. C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br. J. Pharmacol., 2007, 152 (5), 815-824.
202. Abe, T.; Kakyo, M.; Tokui, T.; Nakagomi, R.; Nishio, T.; Nakai, D.; Nomura, H.; Unno, M.; Suzuki, M.; Naitoh, T.; Matsuno, S.; Yawo, H. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Bio Chem, 1999, 274 (24), 17159-17163.
203. Konig, J.; Cui, Y.; Nies, A. T.; Keppler, D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 278 (1), G156-164.
204. Konig, J.; Cui, Y.; Nies, A. T.; Keppler, D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Bio Chem, 2000, 275 (30), 23161-23168.
205. Abe, T.; Unno, M.; Onogawa, T.; Tokui, T.; Kondo, T. N.; Nakagomi, R.; Adachi, H.; Fujiwara, K.; Okabe, M.; Suzuki, T.; Nunoki, K.; Sato, E.; Kakyo, M.; Nishio, T.; Sugita, J.; Asano, N.; Tanemoto, M.; Seki, M.; Date, F.; Ono, K.; Kondo, Y.; Shiiba, K.; Suzuki, M.; Ohtani, H.; Shimosegawa, T.; Iinuma, K.; Nagura, H.; Ito, S.; Matsuno, S. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology, 2001, 120 (7), 1689-1699.
206. Kobayashi, D.; Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther., 2003, 306 (2), 703-708.
207. Grube, M.; Kock, K.; Oswald, S.; Draber, K.; Meissner, K.; Eckel, L.; Bohm, M.; Felix, S. B.; Vogelgesang, S.; Jedlitschky, G.; Siegmund, W.; Warzok, R.; Kroemer, H. K. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther., 2006, 80 (6), 607-620.
208. St-Pierre, M. V.; Hagenbuch, B.; Ugele, B.; Meier, P. J.; Stallmach, T. Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J. Clin. Endocrinol. Metab., 2002, 87 (4), 1856-1863.
209. Satoh, H.; Yamashita, F.; Tsujimoto, M.; Murakami, H.; Koyabu, N.; Ohtani, H.; Sawada, Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos., 2005, 33 (4), 518-523.
210. Hosoyamada, M.; Sekine, T.; Kanai, Y.; Endou, H. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol., 1999, 276 (1), F122-F128.
211. Whitley, A. C.; Sweet, D. H.; Walle, T. The dietary polyphenol ellagic acid is a potent inhibitor of hOAT1. Drug Metab. Dispos., 2005, 33 (8), 1097-1100.
212. Hong, S. S.; Seo, K.; Lim, S. C.; Han, H. K. Interaction characteristics of flavonoids with human organic anion transporter 1 (hOAT1) and 3 (hOAT3). Pharmacol. Res., 2007, 56 (6), 468-473.
213. Cha, S. H.; Sekine, T.; Fukushima, J. I.; Kanai, Y.; Kobayashi, Y.; Goya, T.; Endou, H. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol., 2001, 59 (5), 1277-1286.
214. Ohtsuki, S.; Kikkawa, T.; Mori, S.; Hori, S.; Takanaga, H.; Otagiri, M.; Terasaki, T. Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J. Pharmacol. Exp. Ther., 2004, 309 (3), 1273-1281.
215. Sweet, D. H.; Miller, D. S.; Pritchard, J. B.; Fujiwara, Y.; Beier, D. R.; Nigam, S. K. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Bio Chem, 2002, 277 (30), 26934-26943.
216. Imai, Y.; Tsukahara, S.; Asada, S.; Sugimoto, Y. Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2- mediated multidrug resistance. Cancer Res., 2004, 64 (12), 4346-4352.
217. Zhang, S.; Morris, M. E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther., 2003, 304 (3), 1258-1267.
218. Zhang, S. Z.; Yang, X. N.; Morris, M. E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol., 2004, 65 (5), 1208-1216.
219. Chearwae, W.; Shukla, S.; Limtrakul, P.; Ambudkar, S. V. Modulation of the function of the multidrug resistance-linked ATPbinding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther., 2006, 5 (8), 1995-2006.
220. Hong, J.; Lambert, J. D.; Lee, S. H.; Sinko, P. J.; Yang, C. S. Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun, 2003, 310 (1), 222-227.
221. Shirasaka, Y.; Kuraoka, E.; Spahn-Langguth, H.; Nakanishi, T.; Langguth, P.; Tamai, I. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J. Pharmacol. Exp. Ther., 2010, 332 (1), 181-189.
222. Nabekura, T.; Kamiyama, S.; Kitagawa, S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun., 2005, 327 (3), 866-870.
223. Cooray, H. C.; Janvilisri, T.; van Veen, H. W.; Hladky, S. B.; Barrand, M. A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun., 2004, 317 (1), 269-275.